DiaMedica Therapeutics Inc. (DMAC) PT Lowered to $14 at Lake Street Capital Markets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts DMAC Hot Sheet
Price: $8.72 +1.04%
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
9 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Lake Street Capital Markets analyst Thomas Flaten lowered the price target on DiaMedica Therapeutics Inc. (NASDAQ: DMAC) to $14.00 (from $21.00) while maintaining a Buy rating.
Despite the lower price target, the analyst noted positive momentum in the stroke study.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DiaMedica hits 200-patient mark in stroke trial, interim analysis due
- CACI International (CACI) PT Lowered to $823 at UBS
- AppFolio (APPF) PT Raised to $250 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
